Pharma has plenty of examples of things like that. Discovery is made, nobody thinks it’s worth pursuing, the world and knowledge base changes, someone goes back and says “this deserves another look”.

A lot of the GLP-1 success is based on progress made in the diabetes space (incidentally so), the refinement of molecules and better understanding of how obesity could be treated.